학술논문
A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo.
Document Type
Article
Author
Ebert, Tim; Smith, Sharon; Pancari, Greg; Clark, Desmond; Hampton, Richard; Secore, Susan; Towne, Victoria; Hongxia Fan; XinMin Wang; Xiaoqing Wu; Ernst, Robin; Harvey, Barrett R.; Finnefrock, Adam C.; Fubao Wang; Tan, Charles; Durr, Eberhard; Cope, Leslie; Anderson, Annaliesa; Zhiqiang An; McNeely, Tessie
Source
Subject
*STAPHYLOCOCCUS aureus
*STAPHYLOCOCCUS
*MONOCLONAL antibody probes
*LABORATORY rats
*BINDING sites
*
*
*
*
Language
ISSN
1093-2607
Abstract
A fully human monoclonal antibody (CS-D7, IgG_1) specific for the iron regulated surface determinant B (IsdB) of Staphylococcus aureus was isolated from the Cambridge Antibody Technology (CAT) scFv antibody library. As compared to previously described IsdB specific murine monoclonals, CS-D7 has a unique, non-overlapping binding site on IsdB, and exhibits increased in vivo activity. The antibody recognizes a conformational epitope spanning amino acids 50 to 285 and has a binding affinity of 340 (± 75) pM for IsdB. CS-D7 bound to a wide variety of S. aureus strains, but not to an isdB deletion mutant. The antibody mediated opsonophagocytic (OP) killing in vitro and mediated significant protection in vivo. In a murine lethal sepsis model, the antibody conferred protection from death when dosed prior to challenge, but not when dosed after challenge. Importantly, in a central venous catheter (CVC) model in rats, the antibody reduced bacteremia and prevented colonization of indwelling catheters. Protection was observed when rats were dosed with CS-D7 prior to challenge as well as post challenge. IsdB is currently being investigated for clinical efficacy against S. aureus infection, and the activity of this human IsdB specific antibody supplements the growing body of evidence to support targeting this antigen for vaccine development. [ABSTRACT FROM AUTHOR]